Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
Resectable borderline pancreatic adenocarcinoma
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Vectibix 20 mg/ml concentrate for solution for infusion, Folinato Cálcico Hikma, 10 mg/ml solución inyectable y para perfusión EFG, Oxaliplatino Kabi 5 mg/ml concentrado para solución para perfusión EFG, Erbitux 5 mg/mL solution for infusion, Irinotecan Hydrochloride Trihydrate Fair-Med Healthcare 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG
Disc Medicine
Colorectal cancer and metastatic disease limited to the liver with bad prognosis.
1 trial -
Calcium Folinate 10 mg/ml Solution for injection or infusion, Irinotecanhydrochloridetrihydraat Hikma 20 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Avastin 25 mg/ml concentrate for solution for infusion., Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
Patients with colorectal peritoneal metastases with a PCI-score of 1-20
1 trial -
Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion
Janssen-Cilag International N.V.
Head and Neck Squamous Cell Carcinoma
1 trial -
Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion
AstraZeneca AB
Solid Tumors, SQ, NSQ NSCLC
1 trial -
Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent
Hoffmann-La Roche
Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline
Tumours, Gynecological
1 trial -
Esmolol HCl LYO Orpha 2500 mg poeder voor concentraat voor oplossing voor infusie, Milrinon Hikma 1 mg/ml oplossing voor injectie, Dobutamine-hameln 5 mg/ml i.v. infusievloeistof, oplossing voor infusie
Disc Medicine
Cardiogenic shock
1 trial -
FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,
The George Institute
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
1 trial -
FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio
CERO THERAPEUTICS HOLDINGS, INC.
colorectal cancer
1 trial -
Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co
Boehringer Ingelheim
gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma
1 trial -
Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL , IRINOTECAN , Fluorouracil Hikma 50 mg/ml Injektionslösung, Ribofolin® 10 mg/ml Injektionslösung, JNJ-61186372, OXALIPLATIN , CALCIUM FOLINATE , JNJ-61186372, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FU medac 50 mg/ml, Injektionslösung
Janssen-Cilag International N.V.
Advanced or Metastatic Colorectal Cancer
1 trial -
Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, PALBOCICLIB, Palbociclib, TEMOZOLOMIDE, TEMOZOLOMIDE, PALBOCICLIB, PALBOCICLIB, TEMOZOLOMIDE, Temozolomide SUN 5 mg hard capsules, Endoxan®, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion
Pfizer Australia Pty Ltd
recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma
1 trial -
Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.
Boehringer Ingelheim
locally advanced or metastatic NSCLC
1 trial -
Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para
Lacuna Pharma Pty Ltd
Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
1 trial -
Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion, REGN7075, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., LIBTAYO 350 mg concentrate for solution for infusion., Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer
1 trial -
Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml Infusionslösung, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslös
Gilead Sciences Pty Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione
Fondazione Telethon ETS
stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile
Astellas Pharma GmbH
FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
1 trial -
Citarabina Hikma 2 g/20mL Soluzione Iniettabile, Idarubicin Hikma 1 mg/ml Injektionslösung, Cytarabine 100 mg/ml Solution for Injection or Infusion, Cytarabine 100 mg/ml Solution for Injection or Infusion, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, JNJ-75276617, JNJ-75276617 (G022), Venclyxto 100 mg film-coated tablets, Idarubicin, Venclyxto 100 mg film-coated tablets, JNJ-75276617, JNJ-75276617 (G023), Azacitidine, JNJ-75276617, Citarabina Hikma 500mg/5mL Soluzione I
Janssen-Cilag International N.V.
Acute Myeloid Leukemia
1 trial -
Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre
Revolution Medicines
Lung Cancer
1 trial -
Amiodarone Hikma 50 mg/ml soluzione iniettabile, BUPISEN 5 mg/ml soluzione iniettabile, Lidocaina Kabi 20 mg/ml soluzione iniettabile
Fondazione Telethon ETS
electrical storm
1 trial -
Ceftriaxon Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie, Ceftazidim Fresenius Kabi 500 mg poeder voor oplossing voor injectie, Amoxicilline/Clavulaanzuur Sandoz 2000 mg/200 mg i.v., poeder voor oplossing voor intraveneuze infusie, Cefuroxim Hikma 1500 mg poeder voor oplossing voor injectie of infusie, Meropenem CF 1000 mg, poeder voor oplossing voor injectie of infusie, Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie, Piperacilline/Tazobactam Fresenius Kabi 2
Disc Medicine
Sepsis
1 trial -
IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Rixathon 500 mg concentrate for solution for infusion, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, Rixathon 100 mg concentrate for solution for infusion, MTX HEXAL 2,5 mg Tabletten, -, Methotrexat-GRY® 50 mg/2 ml Injektionslösung, ASFOTASE ALFA
Alexion Europe SAS
HYPOPHOSPHATASIA
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources